Investors
Company Name: Protein Sciences Corporation
Founded: 1983
Corporate Headquarters:
1000 Research Parkway, Meriden CT 06450
- Executive Offices, Pilot Plant cGMP Manufacturing, Quality Assurance, Process Development
Other Locations:
875 Research Parkway, Meriden CT 06450
- Business Development, Finance, Quality Control, Regulatory Affairs, Large Scale cGMP Manufacturing (projected to be operational in 2010)
Funding Sources:
Management and Private Investors
- Pacific Rim Ventures (Japan)
Nosan Corporation (Japan)
Diamyd Medical (Sweden)
Wyeth
Development Partners
- UMN Pharma (Japan)
Diamyd Medical (Sweden)
Government Contracts
- National Institute of Allergy and Infectious Diseases (NIAID): N01-AI-30023 Development and Production of a Recombinant Subunit Cornonavirus-SARS Vaccine for Use in Phase I/II Clinical Trials
- National Institute of Allergy and Infectious Diseases (NIAID): HHSN272200800055C Advanced Development of Multivalent Filovirus (Ebola and Marburg) Hemorrhagic Fever Vaccines
- National Heart, Lung and Blood Institute (NHLBI): HHSN268200625238C Insect Cell rAAV Particle cGMP Process Development
- Department of Defense (DoD): W911SR-06-C-0010 Improved Protein Manufacturing in Insect Expression Systems
- Department of Homeland Security (DHS): HSHQDC-07-P-00081 Foot and Mouth Disease Virus (FMDV) Vaccines and Antivirals Project
Investor Relations Contact:
Dan Adams
President and Chief Executive Officer
1-203-686-0800
Shareholder Relations Contact:
Brenda Sullivan
Finance Manager
1-203-599-6064 x151
Financial Profile
Protein Sciences Corporation (PSC) is a privately held company that was founded in 1983. The Company has completed five rounds of equity financing and has raised over $45M including several million in non-equity licensing fees. PSC generates revenue through the GeneXpress service business, research proteins business and technology licenses. In 2007, the revenue from the service and product business was more than $6M million and in 2008 more than $8 million. Total revenues since the Company's founding exceed $75M.
PSC filed a Biologics License Application (BLA) for its lead product FluBlok® with the U.S. FDA in April 2008, seeking licensure under the Accelerated Approval pathway. FluBlok has been granted Fast Track and priority review status. The FDA has inspected PSC's manufacturing facility and has provided a list of items that are being addressed in anticipation of licensure. PSC anticipates FDA approval of the FluBlok vaccine for use in people 18 years of age and older for the 2009/10 influenza season.
